Cancer arises from somatic mutations accumulating within a cell, disrupting crucial regulatory pathways governing cell growth and division.  Advances in genomic sequencing have revolutionized our understanding of the genetic basis of cancer, revealing the complex interplay of driver and passenger mutations across diverse tumor types.  This intricate genomic landscape facilitates the development of personalized medicine approaches.  Next-generation sequencing (NGS) allows identification of specific oncogenic mutations, informing targeted therapies.  For example, the presence of EGFR mutations in lung cancer predicts response to EGFR tyrosine kinase inhibitors.  Furthermore, understanding the tumor's mutational burden can guide immunotherapy selection, with high mutational load often correlating with improved response to immune checkpoint inhibitors.  Ongoing research focuses on incorporating epigenetic alterations, transcriptomic profiles, and proteomic data to further refine personalized cancer treatment strategies.  Integration of these multi-omics datasets holds the potential to predict treatment response, minimize adverse effects, and ultimately enhance cancer patient outcomes.